https://op.europa.eu/en/web/public-procurement/procurement-details/-/procurement/58e018b9-eb78-4ca4-922c-48a0d9950395
Immunosuppressants - Etrasimod I. - EU tenders - Publications Office of the EU
eu tenderspublications officeimmunosuppressantsetrasimod
https://catalogues.ema.europa.eu/node/4799/administrative-details
An Active Surveillance, Post-Authorization Safety Study to Characterize the Safety of Etrasimod in...
https://www.prnewswire.com/news-releases/arena-reports-third-quarter-financial-results-with-strong-cash-position-advancing-etrasimod-into-a-phase-3-registrational-program-in-atopic-dermatitis-301169036.html
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a...
/PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended...
https://www.nice.org.uk/guidance/ta956/chapter/4-Evaluation-committee-members-and-NICE-project-team
4 Evaluation committee members and NICE project team | Etrasimod for treating moderately to...
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over
https://www.nice.org.uk/guidance/ta956/chapter/1-Recommendations
1 Recommendations | Etrasimod for treating moderately to severely active ulcerative colitis in...
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65171e4a-d136-4abc-b08c-c40c1b486ff6
DailyMed - VELSIPITY- etrasimod tablet, film coated
dailymedetrasimodtabletfilmcoated
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-advancing-etrasimod-into-phase-3-program-in-atopic-dermatitis-ad-reports-compelling-topline-results-from-phase-2b-advise-trial-301169037.html
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports...
/PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a...